Cell-free circulating tumour DNA as a liquid biopsy in breast cancer

Leticia De Mattos-Arruda; Carlos Caldas

doi:10.1016/j.molonc.2015.12.001

Cell-free circulating tumour DNA as a liquid biopsy in breast cancer

Leticia De Mattos-Arruda
, Carlos Caldas^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

111 Scopus citations

Abstract

Recent developments in massively parallel sequencing and digital genomic techniques support the clinical validity of cell-free circulating tumour DNA (ctDNA) as a 'liquid biopsy' in human cancer. In breast cancer, ctDNA detected in plasma can be used to non-invasively scan tumour genomes and quantify tumour burden. The applications for ctDNA in plasma include identifying actionable genomic alterations, monitoring treatment responses, unravelling therapeutic resistance, and potentially detecting disease progression before clinical and radiological confirmation. ctDNA may be used to characterise tumour heterogeneity and metastasis-specific mutations providing information to adapt the therapeutic management of patients. In this article, we review the current status of ctDNA as a 'liquid biopsy' in breast cancer.

Original language	English
Pages (from-to)	464-474
Number of pages	11
Journal	Molecular Oncology
Volume	10
Issue number	3
DOIs	https://doi.org/10.1016/j.molonc.2015.12.001
State	Published - 1 Mar 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2015 Federation of European Biochemical Societies.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Breast cancer
Circulating cell-free tumour DNA
Heterogeneity
Monitoring
Resistance
Stratification

Access to Document

10.1016/j.molonc.2015.12.001

Cite this

@article{f67926c1938a4502bdca160b3d019508,

title = "Cell-free circulating tumour DNA as a liquid biopsy in breast cancer",

abstract = "Recent developments in massively parallel sequencing and digital genomic techniques support the clinical validity of cell-free circulating tumour DNA (ctDNA) as a 'liquid biopsy' in human cancer. In breast cancer, ctDNA detected in plasma can be used to non-invasively scan tumour genomes and quantify tumour burden. The applications for ctDNA in plasma include identifying actionable genomic alterations, monitoring treatment responses, unravelling therapeutic resistance, and potentially detecting disease progression before clinical and radiological confirmation. ctDNA may be used to characterise tumour heterogeneity and metastasis-specific mutations providing information to adapt the therapeutic management of patients. In this article, we review the current status of ctDNA as a 'liquid biopsy' in breast cancer.",

keywords = "Breast cancer, Circulating cell-free tumour DNA, Heterogeneity, Monitoring, Resistance, Stratification",

author = "\{De Mattos-Arruda\}, Leticia and Carlos Caldas",

note = "Publisher Copyright: {\textcopyright} 2015 Federation of European Biochemical Societies.",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.molonc.2015.12.001",

language = "אנגלית",

volume = "10",

pages = "464--474",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Cell-free circulating tumour DNA as a liquid biopsy in breast cancer

AU - De Mattos-Arruda, Leticia

AU - Caldas, Carlos

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Recent developments in massively parallel sequencing and digital genomic techniques support the clinical validity of cell-free circulating tumour DNA (ctDNA) as a 'liquid biopsy' in human cancer. In breast cancer, ctDNA detected in plasma can be used to non-invasively scan tumour genomes and quantify tumour burden. The applications for ctDNA in plasma include identifying actionable genomic alterations, monitoring treatment responses, unravelling therapeutic resistance, and potentially detecting disease progression before clinical and radiological confirmation. ctDNA may be used to characterise tumour heterogeneity and metastasis-specific mutations providing information to adapt the therapeutic management of patients. In this article, we review the current status of ctDNA as a 'liquid biopsy' in breast cancer.

AB - Recent developments in massively parallel sequencing and digital genomic techniques support the clinical validity of cell-free circulating tumour DNA (ctDNA) as a 'liquid biopsy' in human cancer. In breast cancer, ctDNA detected in plasma can be used to non-invasively scan tumour genomes and quantify tumour burden. The applications for ctDNA in plasma include identifying actionable genomic alterations, monitoring treatment responses, unravelling therapeutic resistance, and potentially detecting disease progression before clinical and radiological confirmation. ctDNA may be used to characterise tumour heterogeneity and metastasis-specific mutations providing information to adapt the therapeutic management of patients. In this article, we review the current status of ctDNA as a 'liquid biopsy' in breast cancer.

KW - Breast cancer

KW - Circulating cell-free tumour DNA

KW - Heterogeneity

KW - Monitoring

KW - Resistance

KW - Stratification

UR - https://www.scopus.com/pages/publications/84959105405

U2 - 10.1016/j.molonc.2015.12.001

DO - 10.1016/j.molonc.2015.12.001

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 26776681

AN - SCOPUS:84959105405

SN - 1574-7891

VL - 10

SP - 464

EP - 474

JO - Molecular Oncology

JF - Molecular Oncology

IS - 3

ER -

Cell-free circulating tumour DNA as a liquid biopsy in breast cancer

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this